Cargando…

Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis

OBJECTIVE: Deficiencies in klotho are implicated in various kidney dysfunctions including diabetic nephropathy (DN) related to inflammatory responses. Klotho is closely related to inflammatory responses and is a potential target for ameliorating kidney failure. Pyroptosis, an inflammatory form of pr...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jiaxin, Cui, Jialin, Shi, Yimin, Wang, Tao, Xin, Junyan, Li, Yimeng, Shan, Xiaomeng, Zhu, Zhiyao, Gao, Yanbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228232/
https://www.ncbi.nlm.nih.gov/pubmed/37261217
http://dx.doi.org/10.1155/2023/7423661
_version_ 1785050924327108608
author He, Jiaxin
Cui, Jialin
Shi, Yimin
Wang, Tao
Xin, Junyan
Li, Yimeng
Shan, Xiaomeng
Zhu, Zhiyao
Gao, Yanbin
author_facet He, Jiaxin
Cui, Jialin
Shi, Yimin
Wang, Tao
Xin, Junyan
Li, Yimeng
Shan, Xiaomeng
Zhu, Zhiyao
Gao, Yanbin
author_sort He, Jiaxin
collection PubMed
description OBJECTIVE: Deficiencies in klotho are implicated in various kidney dysfunctions including diabetic nephropathy (DN) related to inflammatory responses. Klotho is closely related to inflammatory responses and is a potential target for ameliorating kidney failure. Pyroptosis, an inflammatory form of programmed cell death, is reported to take part in DN pathogenesis recently. This study is aimed at exploring whether and how klotho inhibited podocyte pyroptosis and whether astragaloside IV (AS-IV) protect podocyte through the regulation of klotho. MATERIALS AND METHODS: SD rat model of DN and conditionally immortalized mouse podocytes exposed to high glucose were treated with AS-IV. Biochemical assays and morphological examination, cell viability assay, cell transfection, phalloidin staining, ELISA, LDH release assay, SOD and MDA detection, MMP assay, ROS level detection, flow cytometry analysis, TUNEL staining assay, PI/Hoechst 33342 staining, immunofluorescence assay, and western blot were performed to elucidate podocyte pyroptosis and to observe the renal morphology. RESULTS: The treatment of AS-IV can improve renal function and protect podocytes exposed to high glucose. Klotho was decreased, and AS-IV increased klotho levels in serum and kidney tissue of DN rats as well as podocytes exposed to high glucose. AS-IV can inhibit DN glomeruli pyroptosis in vivo. In vitro, overexpressed klotho and treatment with AS-IV inhibited pyroptosis of podocytes cultured in high glucose. Klotho knockdown promoted podocyte pyroptosis, and treatment with AS-IV reversed this effect. Furthermore, the overexpression of klotho and AS-IV reduces oxidative stress levels and inhibited NF-κB activation and NLRP3-mediated podocytes' pyroptosis which was abolished by klotho knockdown. In addition, both the ROS inhibitor NAC and the NF-κB pathway inhibitor PDTC can inhibit NLRP3 inflammasome activation. NLRP3 inhibitor MCC950 can inhibit pyroptosis of podocytes exposed to high glucose. CONCLUSION: Altogether, our results demonstrate that the protective effect of AS-IV in upregulating klotho expression in diabetes-induced podocyte injury is associated with the inhibition of NLRP3-mediated pyroptosis via the NF-κB signaling pathway.
format Online
Article
Text
id pubmed-10228232
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-102282322023-05-31 Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis He, Jiaxin Cui, Jialin Shi, Yimin Wang, Tao Xin, Junyan Li, Yimeng Shan, Xiaomeng Zhu, Zhiyao Gao, Yanbin J Diabetes Res Research Article OBJECTIVE: Deficiencies in klotho are implicated in various kidney dysfunctions including diabetic nephropathy (DN) related to inflammatory responses. Klotho is closely related to inflammatory responses and is a potential target for ameliorating kidney failure. Pyroptosis, an inflammatory form of programmed cell death, is reported to take part in DN pathogenesis recently. This study is aimed at exploring whether and how klotho inhibited podocyte pyroptosis and whether astragaloside IV (AS-IV) protect podocyte through the regulation of klotho. MATERIALS AND METHODS: SD rat model of DN and conditionally immortalized mouse podocytes exposed to high glucose were treated with AS-IV. Biochemical assays and morphological examination, cell viability assay, cell transfection, phalloidin staining, ELISA, LDH release assay, SOD and MDA detection, MMP assay, ROS level detection, flow cytometry analysis, TUNEL staining assay, PI/Hoechst 33342 staining, immunofluorescence assay, and western blot were performed to elucidate podocyte pyroptosis and to observe the renal morphology. RESULTS: The treatment of AS-IV can improve renal function and protect podocytes exposed to high glucose. Klotho was decreased, and AS-IV increased klotho levels in serum and kidney tissue of DN rats as well as podocytes exposed to high glucose. AS-IV can inhibit DN glomeruli pyroptosis in vivo. In vitro, overexpressed klotho and treatment with AS-IV inhibited pyroptosis of podocytes cultured in high glucose. Klotho knockdown promoted podocyte pyroptosis, and treatment with AS-IV reversed this effect. Furthermore, the overexpression of klotho and AS-IV reduces oxidative stress levels and inhibited NF-κB activation and NLRP3-mediated podocytes' pyroptosis which was abolished by klotho knockdown. In addition, both the ROS inhibitor NAC and the NF-κB pathway inhibitor PDTC can inhibit NLRP3 inflammasome activation. NLRP3 inhibitor MCC950 can inhibit pyroptosis of podocytes exposed to high glucose. CONCLUSION: Altogether, our results demonstrate that the protective effect of AS-IV in upregulating klotho expression in diabetes-induced podocyte injury is associated with the inhibition of NLRP3-mediated pyroptosis via the NF-κB signaling pathway. Hindawi 2023-05-22 /pmc/articles/PMC10228232/ /pubmed/37261217 http://dx.doi.org/10.1155/2023/7423661 Text en Copyright © 2023 Jiaxin He et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
He, Jiaxin
Cui, Jialin
Shi, Yimin
Wang, Tao
Xin, Junyan
Li, Yimeng
Shan, Xiaomeng
Zhu, Zhiyao
Gao, Yanbin
Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
title Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
title_full Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
title_fullStr Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
title_full_unstemmed Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
title_short Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
title_sort astragaloside iv attenuates high-glucose-induced impairment in diabetic nephropathy by increasing klotho expression via the nf-κb/nlrp3 axis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228232/
https://www.ncbi.nlm.nih.gov/pubmed/37261217
http://dx.doi.org/10.1155/2023/7423661
work_keys_str_mv AT hejiaxin astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT cuijialin astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT shiyimin astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT wangtao astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT xinjunyan astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT liyimeng astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT shanxiaomeng astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT zhuzhiyao astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis
AT gaoyanbin astragalosideivattenuateshighglucoseinducedimpairmentindiabeticnephropathybyincreasingklothoexpressionviathenfkbnlrp3axis